Time on boards
- Boards served
- 1
- Current seats
- 1
- Board service
- 4 years
- Director since
- 2023
4 years of board service in total across 1 board, counting each seat separately. Longest: Voyager Therapeutics Inc., 3 years.
Voyager Therapeutics Inc.
Director
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Feb 13, 2025 | Neurocrine Biosciences Inc. | Option exercise | +2,717 | — | — |
| Feb 13, 2025 | Neurocrine Biosciences Inc. | Open-market sale | −1,432 | $116.83 | $167,301 |
| Feb 13, 2025 | Neurocrine Biosciences Inc. | Option exercise | +2,690 | — | — |
| Feb 13, 2025 | Neurocrine Biosciences Inc. | Open-market sale | −1,447 | $116.75 | $168,937 |
| Jan 31, 2025 | Neurocrine Biosciences Inc. | Option exercise | +238 | — | — |
| Jan 31, 2025 | Neurocrine Biosciences Inc. | Open-market sale | −126 | $152.97 | $19,274 |
| Nov 29, 2024 | Neurocrine Biosciences Inc. | Option exercise | +4,426 | — | — |
| Nov 29, 2024 | Neurocrine Biosciences Inc. | Open-market sale | −2,331 | $126.29 | $294,382 |
| Feb 13, 2024 | Neurocrine Biosciences Inc. | Open-market sale | −1,432 | $132.94 | $190,370 |
| Jan 31, 2024 | Neurocrine Biosciences Inc. | Open-market sale | −126 | $141.94 | $17,884 |
| Nov 29, 2023 | Neurocrine Biosciences Inc. | Open-market sale | −2,331 | $113.57 | $264,732 |
| Aug 21, 2023 | Neurocrine Biosciences Inc. | Open-market sale | −3,198 | $107.37 | $343,369 |
| Feb 7, 2023 | Neurocrine Biosciences Inc. | Open-market sale | −4,508 | $102.30 | $461,168 |
| Jan 31, 2023 | Neurocrine Biosciences Inc. | Open-market sale | −126 | $108.48 | $13,668 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.